NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
New data reinforces findings from MINDACT supporting MammaPrint® in predicting chemotherapy benefit for distant recurrence free interval among patients with HR+HER2-early-stage breast cancer IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 11, 2024 – Read More
Agendia Announces Publication Validating MammaPrint Utility in Prediction of Extended Endocrine Therapy Benefit
A secondary analysis of the randomized controlled trial, IDEAL, confirms results from NSABP B-42 demonstrating MammaPrint is predictive of extended endocrine therapy benefit IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 2, 2024 – Read More
Agendia to Unveil New Findings in Early-Stage Breast Cancer at San Antonio Breast Cancer Symposium 2024
New data reinforces MammaPrint® and BluePrint® tests’ expanding clinical utility to optimize treatment selection. IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – November 25, 2024 – Agendia®, Inc., announced today that new data on its Read More











